1. Home
  2. NPV vs CHRS Comparison

NPV vs CHRS Comparison

Compare NPV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Virginia Quality Municipal Income Fund

NPV

Nuveen Virginia Quality Municipal Income Fund

HOLD

Current Price

$9.60

Market Cap

184.3M

Sector

Finance

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.02

Market Cap

159.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPV
CHRS
Founded
1993
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.3M
159.1M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
NPV
CHRS
Price
$9.60
$1.02
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $7.75
AVG Volume (30 Days)
125.2K
★ 1.3M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 3.90%
N/A
EPS Growth
N/A
★ 472.00
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$44.19
Revenue Next Year
N/A
$65.06
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.05
$0.94
52 Week High
$11.81
$2.62

Technical Indicators

Market Signals
Indicator
NPV
CHRS
Relative Strength Index (RSI) 48.56 40.32
Support Level $9.05 $0.97
Resistance Level $11.61 $1.53
Average True Range (ATR) 0.15 0.07
MACD 0.07 0.00
Stochastic Oscillator 67.86 36.84

Price Performance

Historical Comparison
NPV
CHRS

About NPV Nuveen Virginia Quality Municipal Income Fund

Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. The company mostly invests in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities, Housing/Multifamily, Transportation, and Others.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: